MOLECULAR PARTNERS SF 1

Research MOLECULAR PARTNERS SF 1 (6ML) on Bullrun: market cap EUR 124.54M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6ML
• ExchangeF
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 124.54M
• Financial periodQ4 2025
• Net income-EUR 12.65M
• Free cash flow-EUR 11.29M

Valuation Snapshot

latest market cap is EUR 124.54M.

About MOLECULAR PARTNERS SF 1

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia;

Frequently asked questions

What is MOLECULAR PARTNERS SF 1's market cap?

MOLECULAR PARTNERS SF 1's market capitalization is EUR 124.54M.

What does MOLECULAR PARTNERS SF 1 do?

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.